Alexandros Makriyannis

Alexandros Makriyannis is a distinguished scientist and researcher in the field of medicinal chemistry, particularly known for his contributions to endocannabinoid research. Here are some key details about his background and accomplishments:

Academic Positions

• George Behrakis Chair of Pharmaceutical Biotechnology at Northeastern University
• Founder and Director of the Center for Drug Discovery at Northeastern University
• Distinguished Professor of Pharmaceutical Sciences, Chemistry, and Chemical Biology at Northeastern University13

Research Focus

Makriyannis has spent over four decades studying the endocannabinoid system, which regulates various physiological functions including pain, neuroprotection, addiction, immunomodulation, and cognition.23 His work has involved:

• Designing and synthesizing key pharmacological endocannabinoid probes
• Developing new medications based on his research
• Investigating the molecular basis of cannabinoid activity
• Pioneering the field of chemical biology by combining medicinal chemistry, biochemistry, molecular biology, and biophysics3

Achievements and Recognition

• Published over 600 peer-reviewed manuscripts and holds more than 40 patents15
• Founded two biotechnology startups: MAKScientific (2004) and PafosPharma (2014)5
• Received numerous awards, including:
  • ACS Medicinal Chemistry Hall of Fame (2013)
  • ACS Research Lifetime Achievement Award in Medicinal Chemistry (2012)
  • AAPS Distinguished Pharmaceutical Scientist Award (2015)
  • CPDD Nathan B. Eddy Memorial Award (2018)16

Education

• Ph.D. in Medicinal Chemistry from the University of Kansas
• Post-doctoral fellowship in Synthetic Organic Chemistry at the University of California, Berkeley
• Bachelor's Degree in Pharmaceutical Chemistry from the University of Cairo4

Makriyannis is widely recognized for his innovative approach to drug discovery and his significant contributions to the understanding of the endocannabinoid system. His work has led to the development of compounds currently in advanced preclinical trials for treating various conditions, including metabolic disorders, liver function issues, neuropathic pain, addiction, and neurodegenerative diseases.23